Guggenheim lifts target for Elevance Health stock to USD 460

Published on 10/14/2026 at 15:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 49.83 billion in the second quarter of 2026. Elevance Health stock costs EUR 381.15 on October 14, 2026 at 3:02 p.m. CEST.

Target and earnings date

On October 12, 2026, Guggenheim lifted its Elevance Health target from USD 455.00 to USD 460.00.
Revenue reached USD 49.83 billion in the second quarter of 2026, up 0.80 percent year over year.
Elevance Health stock costs EUR 381.15 at Lang & Schwarz on October 14, 2026 at 3:02 p.m. CEST.
Elevance Health is scheduled to report third-quarter 2026 results on October 21, 2026.

Modernes Krankenhaus-Campus mit Glasfassade und Patienten im Eingangsbereich — Elevance Health Krankenversicherungs-Campus US2855211023 zeigt modernen Gebäudeeingang mit weitläufiger Grünanlage unter blauem Himmel, Illustration mit AI erstellt.

Guggenheim raised its Elevance Health target from USD 455.00 to USD 460.00 on October 12, 2026, while maintaining a Buy rating, according to MarketBeat. The target lies 8.17 percent above the NYSE price of USD 425.27 dated October 13, 2026. Elevance Health stock was trading at EUR 381.15 at Lang & Schwarz on October 14, 2026 at 3:02 p.m. CEST.

Revenue reaches USD 49.83 billion

Elevance Health reported USD 49.83 billion in revenue for the second quarter of 2026, up 0.80 percent from the same quarter a year earlier. The company also reported diluted earnings per share of USD 6.71 and net income attributable to common shareholders of USD 1.46 billion for that period.

MarketBeat reported that the previous quarter delivered USD 7.45 in earnings per share against a USD 6.21 consensus estimate, a USD 1.24 difference. The comparison gives the upcoming report a clear benchmark, particularly because the prior-year quarterly earnings per share were USD 8.84.

Stock stays near its yearly high

The NYSE price of USD 425.27 on October 13, 2026 stood below the 52-week high of USD 436.24 and above the low of USD 274.84. The current level is 2.52 percent below that high, while the latest Lang & Schwarz euro quote places the German trading view at EUR 381.15.

Elevance Health operates in the healthcare sector and medical healthcare plans industry. Its stock trades under ticker ELV on the New York Stock Exchange, where the company had a market capitalization of USD 92.2 billion and a price-to-earnings ratio of 18.90 in the latest available quote.

Results date arrives October 21

Elevance Health said on October 5, 2026 that it will release third-quarter 2026 financial results on October 21, 2026 at 6:00 a.m. EDT, followed by a conference call at 8:30 a.m. EDT, according to Elevance Health. Analysts cited by MarketBeat project USD 49.29 billion in revenue and USD 4.70 in earnings per share for the third quarter of 2026.

Comparison with peers

Elevance Health (NYSE, USD): P/E 18.90, market capitalization USD 92.2 billion.

UnitedHealth Group (NYSE, USD): P/E 21.56, market capitalization USD 343.1 billion.

Humana (NYSE, USD): P/E 39.78, market capitalization USD 50.4 billion.

Euro quote at Lang & Schwarz

Elevance Health stock was trading at EUR 381.15 at Lang & Schwarz on October 14, 2026 at 3:02 p.m. CEST. The latest NYSE close was USD 425.27 on October 13, 2026, while the euro quote provides the current German-market perspective.

The further course of trading is shown by the continuously updated real-time quote of Elevance Health stock.